Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST, to provide a business update and review financial results.
A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005320/en/
Contacts
Investors:
Sara Sherman
investors@exscientia.ai
Media:
media@exscientia.ai
